Download and -blockers - e

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Adrenoceptor
antagonist drugs
Pawitra Pulbutr
M.Sc. In Pharm (Pharmacology)
Objectives
 นิ สติ มีความรูค้ วามเข้าใจถึงเภสัชวิทยา กลไกการออกฤทธิ์ เภสัชจลนศาสตร์
การใช้ประโยชน์ทางคลินิก การเกิดปฏิกริ ยิ าระหว่างยา ของยาที่ออกฤทธิ์ตา้ น
ระบบประสาทซิมพาเทติกทัง้ ชนิ ด -receptor
antagonist และชนิ ด -receptor antagonist
Adrenoceptor blocking agent





Affect many physiological &
pathophysiological functions
In the past… may be called “Sympatholytics”
… Not appropriate
Antagonist or Blocker >>> More appropriate
 blocker…

Pheochromocytoma, Primary hypertension

Hypertension, Ischemic heart disease,
Arrhythmia, Other endocrine disorder
 blocker…
Relative selectivity of antagonist for
adrenoceptors
Basic Pharmacology of -blockers
 Binding with -receptor
 Reversible


Competitive with catecholamine
Phentolamine, Tolazoline, Prazosin,
Labetalol
 Irreversible


Covalent binding
Phenoxybenzamine
 Nitrogen mustard like structure
 Form reactive ethyleneimmonium compound
Reversible blocker
Irreversible blocker
Dose-response curve to NE in the presence of two
different -blockers.
Pharmacologic effects



CVS
-receptor control


Arteriolar tone
Venous tone
-receptor antagonist



Decrease peripheral vascular resistance (TPR)

Decreased BP
May cause postural hypotension or reflex
tachycardia (esp. if 2 also blocked … increase
NE secretion… more tachycardia)
Body compensation in long term use … Increase
blood volume
 Other -blocking effects
 Bladder base & Prostate
 -blocker …



Decrease resistance
Increase urine flow
Use in benign prostatic hyperplasia
(BPH)
-blockers
 Irreversible
blockers

Phenoxybenzamine

Non-selective blocker

Selective 1-blocker
 Reversible

blockers
 Phentolamine,
Tolazoline
 Prazosin family
 Doxazosin, Terazosin,
Tamsulosin
Selective 2-blocker
 Yohimbine
Alfuzosin,
Clinical Pharmacology
Pheochromocytoma
Hypertensive emergencies
Chronic hypertension
Peripheral vascular disease
Local vasoconstrictor excess
Urinary obstruction >> BPH
Male sexual dysfunction
Chronic hypertension
 Prazosin family
 1-selective blockers
 Treatment of mild to moderate
hypertension
 ADRs

Postural hypotension esp. First dose
 Not

use non-selective -blocker
2 blocker … Increase NE release
Urinary obstruction
 Benign


Mostly found in elderly male
Treatment




prostatic hyperplasia (BPH)
Surgery
Drug therapy
1-blocker

Partial reversal of smooth muscle contraction
at prostate and bladder base
Prazosin, Doxazosin, Terazosin, Tamsulosin

Good effective esp. in hypertensive patients
Basic Pharmacology of -blockers
Competitive binding to -receptor
“Isoproterenol” like structure
Difference affinity to 1 or 2 receptor
Pure antagonist
Pure -blocker
Partial agonist
-blocker with intrinsic sympathomimetic
activity (ISA)
Activate -RC… not to maximal response
Interfere endogenous ligand to bind -RC
-blocker with -blocker activity (Mixed)
Labetalol & Carvedilol
Properties of several Beta-blockers


Pharmacological effects
CVS
Decrease BP



Heart



Negative chronotropic & inotropic
Slow arterioventricular conduction
Prolong PR interval (AV node suppression)
Renin Angiotensin Aldosterone (RAA) system …
decrease renin release
Vascular resistance


Inhibit 2-mediated vasodilation

Acute effect >>> Vasoconstriction
Prolong action …. Decrease peripheral vascular
resistance

Decrease renin (RAA)
Respiratory tract
 2-receptor blocking activity
 Bronchoconstriction
 Danger in asthmatic patients !!
 Should select 1-selective blocker …
less bronchoconstriction


Acebutolol, Atenolol, Betaxolol,
Bisoprolol, Celiprolol, Esmolol,
Metoprolol
Use with caution in asthma

Eyes

-blocker … decrease aqueous humor
production …decrease intraocular pressure


Use in glaucoma
Metabolic & endocrine effects




-blocker … Inhibit lipolysis
Inhibit glycogenolysis in liver


May affect hypoglycemia correction ?
Should be use with caution in DM esp. Type 1
Increase LDL
Decrease HDL




Decrease HDL/ LDL ratio
Increase risk of CVS disease
Partial agonist … less effects
- blockers … No effect
Effects not related to -blockade
 Intrinsic
sympathomimetic activity of
partial agonist
 -blocker with ISA (partial agonist)




Acebutolol, Carteolol, Celiprolol,
Labetalol, Penbutolol, Pindolol
May be useful in asthmatic & bradycardia
patients
Less bronchoconstriction
Less bradycardia
Clinical Pharmacology
Hypertension
Ischemic heart disease
Cardiac arrhythmia
Other CVS disorder
Glaucoma
Hyperthyroidism
Neurologic disease
Miscellaneous
Choice of -blocker
 Specific activity of each agent
 Benefit or Risk of each agent


1-selective
Partial agonist
 May not be replaced with others

Only pure antagonist is used in
hyperthyroidism
ADRs
 Propranolol



Rash, Fever, Drug allergy
Sedation, Sleep disturbance, Depression
Less in hydrophillic -blocker…Nadolol,
Atenolol
 Unwanted



-blocking effect
Bronchoconstriction (2) … Asthma
Vasospasm (2) … Peripheral vascular dz.
Use selective 1-blocker
ADRs




Use with caution in CHF patient
Reversal of life threatening -blocker
effect

Isoproterenol, Glucagon

Ca++ channel blocker
Drug Interaction

Severe hypotension, Severe bradycardia, Heart
failure
Taper dose




Prolong use … “RC upregulation”
Sudden stop … RC over stimulation … Danger !
Slowly stop using -blocker in ischemic heart
disease
Especially in short half-life … propranolol,
metoprolol
 Use

with caution in Type 1 DM
-blocker may interfere hypoglycemia
recovery
 2

Use selective 1-selective blocker
 Mask


activation >>> Glycogenolysis
disease/ symptom manifestation
Mask hypoglycemia sign … tachycardia
Mask hyperthyroidism symptom
-blockers
 Pure

antagonists
Propranolol, Nadolol, Sotalol, Timolol
 Selective

1-antagonists
Metoprolol, Esmolol, Celiprolol,
Acebutolol, Atenolol, Betaxolol, Bisoprolol
(MEC 2A 2B)
 Partial
agonist (Blockers with ISA)
 Mixed
antagonist ( and -blockers)


Labetalol, Acebutolol, Carteolol,
Celiprolol, Penbutolol, Pindolol (LA 2C 2P)
Labetalol, Carvedilol
Related documents